REGENCY: Obinutuzumab’s Promise for Lupus Nephritis

from The Lupus Academy · host The Lupus Academy

Join Dr Raquel Faria and Professors Richard Furie and Maria Dall’Era as they discuss the results of the phase 3 REGENCY trial of obinutuzumab for the treatment of lupus nephritis.This episode explores what obinutuzumab could mean for the future management of lupus nephritis. Disclaimer: During Lupus Academy podcast episodes, participants may refer to off label use of medicines forpatients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.

Episode metadata supplied by the publisher feed · Published Feb 28, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

REGENCY: Obinutuzumab’s Promise for Lupus Nephritis

0:00 53:48

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Lupus Academy?

This episode is 53 minutes long.

When was this The Lupus Academy episode published?

This episode was published on February 28, 2025.

Can I download this The Lupus Academy episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!